Braveheart Bio to Participate in Cantor Global Healthcare Conference

Rhea-AI Summary

Braveheart Bio (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy and other serious cardiovascular diseases, will participate in the Cantor Global Healthcare Conference in New York, held September 9-11, 2026.

Management is scheduled for a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. A live webcast and replay will be accessible via the News & Events section of Braveheart Bio’s investor relations website.

Market Context

7095554 shares were recorded as bought in recent insider activity, with no shares sold. That record ...

Analysis

7095554 shares were recorded as bought in recent insider activity, with no shares sold. That record adds ownership context to the conference notice; the available history also included a -8.23% reaction. Subsequent substantive disclosures remain the key watch.

Key Figures

Conference dates: September 9-11 Fireside chat: September 10, 2026 at 3:20 p.m. EDT Announcement date: September 01, 2026

3 metrics

Conference dates September 9-11 Cantor Global Healthcare Conference

Fireside chat September 10, 2026 at 3:20 p.m. EDT Management conference participation

Announcement date September 01, 2026 News release dateline

Historical Context

1 past event · Latest: Aug 07 (Negative)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 07	IPO closing	Negative	-8.2%	Upsized IPO closed after full exercise of underwriters’ additional-share option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The available IPO/offering record showed a negative 24-hour reaction.

Key Terms

hypertrophic cardiomyopathy

1 terms

hypertrophic cardiomyopathy medical

"developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM)"

Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the event.

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com  

FAQ

When will Braveheart Bio (NASDAQ: BRVE) present at the Cantor Global Healthcare Conference 2026?

Braveheart Bio management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. According to Braveheart Bio, this session is part of the Cantor Global Healthcare Conference held September 9-11, 2026 in New York, NY.

How can investors access the Braveheart Bio (BRVE) webcast from the Cantor Global Healthcare Conference?

Investors can access a live webcast of Braveheart Bio’s fireside chat by visiting the News & Events section of the company’s website. According to Braveheart Bio, replay access will be available in a temporary online archive following the event.

Where is the Cantor Global Healthcare Conference 2026 featuring Braveheart Bio (BRVE) being held?

The Cantor Global Healthcare Conference featuring Braveheart Bio is being held in New York, NY from September 9-11, 2026. According to Braveheart Bio, the company’s management fireside chat is scheduled there on September 10, 2026 at 3:20 p.m. EDT.

What type of company is Braveheart Bio (NASDAQ: BRVE), which is presenting at the Cantor Global Healthcare Conference?

Braveheart Bio is a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. According to Braveheart Bio, its participation at the Cantor conference includes a management fireside chat and webcast access for interested parties.

Will a replay of Braveheart Bio’s (BRVE) Cantor Global Healthcare Conference fireside chat be available?

Yes, a replay of Braveheart Bio’s fireside chat will be available in a temporary archive after the event. According to Braveheart Bio, both the live webcast and replay can be accessed via the News & Events section of its investor relations website.